alexa Drugs for Alzheimer's | OMICS International | Abstract
ISSN: 2155-6105

Journal of Addiction Research & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Drugs for Alzheimer's

Gonzalo Emiliano Aranda-Abreu1*, María Elena Hernández-Aguilar1, Marisol Herrera-Rivero2 and Luis Isauro García-Hernández1

1Centro de Investigaciones Cerebrales/Universidad Veracruzana, Cuerpo Académico de Neuroquímica, Xalapa,Veracruz, México

2Doctorado en Ciencias Biomédicas/Universidad Veracruzana, Centro de Investigaciones Biomédicas, Xalapa, Veracruz, México

*Corresponding Author:
Gonzalo Emiliano Aranda-Abreu
Centro de Investigaciones Cerebrales/Universidad Veracruzana
Cuerpo Académico de Neuroquímica
Av. Luis Castelazo Ayala
Km 3.5 Carretera Xalapa-Veracruz 91190; México
Tel: 52 228 8418900 Ext. 13616
Fax: 52 228 8418920
E-mail: [email protected]

Received November 14, 2011; Accepted January 09, 2012; Published January 08, 2012

Citation: Aranda-Abreu GE, Hernández-Aguilar ME, Herrera-Rivero M, García-Hernández LI (2012) Drugs for Alzheimer’s. J Addict Res Ther S5:003. doi:10.4172/2155-6105.S5-003

Copyright: © 2012 Aranda-Abreu GE, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Five drugs are currently approved for the treatment of Alzheimer’s disease; nevertheless, we have faced the challenge to respond to family members of these patients the reason why they observe a limited improvement from these treatments. Although both acetylcholinesterase inhibitors and memantine are correctly designed and they show an adequate performance, we believe the neuronal conditions resulting from the pathophysiology of the disease difficult their proper working in brains affected with Alzheimer’s. Patients should therefore undergo a neuronal rehabilitating therapy that enables these drugs for a more effective performance.

Top